https://www.selleckchem.com/pr....oducts/elacridar-gf1
The remaining 5 studies that included 1422 patients (SR group=559, TACE group=863) were studied for the meta-analysis. The median OS was longer in the SR group (8.2-64 months in SR vs. 6.6-32 months in TACE), proving that SR offered survival benefits. Moreover, the HR for the OS in the TACE group was 1.64 (95% CI, 1.43-1.88) compared to SR group, depicting that TACE was a less favorable option compared to SR. There is evidence that SR may be a better viable option for advanced HCC with PVTT. There is evidence that SR may be a
Like
Comment
Share
